Diacomit
Named-patient access overview. Diacomit is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Diacomit (stiripentol) is an antiepileptic medicine approved by the US Food and Drug Administration in 2018 as adjunctive therapy for seizures associated with Dravet syndrome in patients aged 2 years and older taking clobazam. Dravet syndrome is a rare, severe, genetic, treatment-resistant epileptic encephalopathy that typically begins in the first year of life and is most often caused by a pathogenic variant in the SCN1A gene. Diacomit is approximately marketed by Biocodex, a French pharmaceutical company, and it holds long-standing approval in Europe as an orphan medicine.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Diacomit
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Diacomit is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Diacomit in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Diacomit
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Diacomit if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Diacomit for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Diacomit through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Diacomit. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Diacomit through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Diacomit to a patient?
Reserve Meds sources Diacomit from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Diacomit cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Diacomit?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.